Jefferies analyst Maury Raycroft raised the price target on Taysha Gene Therapies (NASDAQ: TSHA) to $13.00 (from $11.00) while maintaining a Buy rating.

The analyst commented, "TSHA will show updated REVEAL Part A data 2Q (+40%/-10%) around IRSF (6/29-7/1). Co expects to complete enrollment for pivotal (n=15) in 2Q w/ potential for 6-mo interim analysis YE26 (+100%/-40%). BTD mtg in 2Q for prelim discussion on potential BLA filing scenarios (6mo interim, rolling submission, file w/12mos) ahead of interim. Co dosed multiple pts in pivotal w/o tx-related SAEs/DLTs; potential safety disclosure w/ n=15 could be a clearing event (+15-20%)."